Risk factors for MACE following noncardiac surgery for patients with coronary stents

October 7, 2013, The JAMA Network Journals

Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American College of Surgeons 2013 Annual Clinical Congress.

"Approximately 600,000 percutaneous coronary stent procedures are performed annually in the United States. Twelve to 23 percent of these patients undergo noncardiac surgery within 2 years of coronary ," according to background information in the article. Noncardiac surgery after recent coronary stent placement is associated with increased risk of adverse cardiac events. Delaying necessary noncardiac surgery can pose a clinical dilemma for a large number of patients. "Guidelines recommend delaying noncardiac surgery in patients after coronary stent procedures for 1 year after drug-eluting stents (DES) and for 6 weeks after bare metal stents (BMS). The evidence underlying these recommendations is limited and conflicting."

Mary T. Hawn, M.D., M.P.H., of the University of Alabama at Birmingham, and colleagues conducted a study to determine for adverse cardiac events in patients undergoing noncardiac surgery within 24 months of coronary stent implantation. The study included 41,989 Veterans Affairs (VA) and non-VA operations performed within 2 years of a coronary stent implantation between 2000 and 2010. The researchers examined the association between timing of surgery and stent type and major adverse (MACE). The primary outcome for the study was a composite 30-day MACE rate of all-cause mortality, heart attack, and cardiac revascularization.

Within 24 months of 124,844 coronary stent implantations (47.6 percent DES, 52.4 percent BMS), 28,029 patients (22.5 percent) underwent noncardiac operations resulting in 1,980 MACE (4.7 percent). The time from stent placement to surgery was associated with MACE for surgery in the first 6 months after the stent procedure, but not for surgery more than 6 months after the stent procedure. The 3 factors most strongly associated with MACE were nonelective surgical admission, having a heart attack in the 6 months preceding surgery, and a revised cardiac risk index score (comprising independent variables that predict an increased risk for cardiac complications) greater than 2.

MACE rate was 5.1 percent for BMS and 4.3 percent for DES. Stent type was not associated with MACE for surgeries more than 6 months after stent placement.

A case-control analysis of 284 matched pairs of patients found no association between cessation of antiplatelet therapy and MACE.

The authors note that there are several considerations that need to be given to these findings, including that the study sample comprised primarily older male patients, thus limiting the generalizability to women or younger men; the clinical factors that influenced stent selection were largely unavailable so they could not be accounted for in the models, and, accordingly, the results could be confounded by those factors; and many patients underwent more than 1 percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) procedure during the dates of the study, which could result in misclassification bias for time from stent placement to surgery.

"How should the findings by Hawn et al and other recent studies influence the approach for patients who need surgery after stents?" asks Emmanouil S. Brilakis, M.D., Ph.D., and Subhash Banerjee, M.D., of the VA North Texas Health Care System, Dallas, in an accompanying editorial.

"The approach for patients with BMS should not change; these patients usually can undergo surgery within 6 weeks after stent implantation with very low risk of stent thrombosis. For with DES, performed at least 6 months after DES implantation appears to carry low risk for stent thrombosis, especially with contemporary, second-generation DES, which have more biocompatible, durable polymer coatings. Hence, nonurgent operations should be postponed until 6 months after stent implantation."

Explore further: Dual antiplatelet therapy following coronary stent implantation is associated with improved outcomes

More information: doi:10.l001/jama.2013.278787
doi:10.l001/jama.2013.279123

Related Stories

Dual antiplatelet therapy following coronary stent implantation is associated with improved outcomes

July 9, 2013
Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical ...

Study finds 30 percent lower risk of dying for diabetics with bypass surgery vs. stent

September 12, 2013
People with diabetes have a 30 per cent less chance of dying if they undergo coronary artery bypass surgery rather than opening the artery through angioplasty and inserting a stent, a new study has found.

1-year results of ADAPT-DES trial published in The Lancet

July 26, 2013
Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less ...

Biodegradable stent proves non-inferior to drug-eluting stent

May 21, 2013
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...

Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation

September 2, 2013
A new article in the September 2013 issue of Thrombosis and Haemostasis strives to shed light on the optimal antithrombotic strategy in patients suffering from atrial fibrillation who undergo coronary stent implantation. ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.